Kedokteran & Kesehatan editorial
Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial
The core problem
Innovation
The PACMAN-AMI trial was a double-blind, placebo-controlled, randomized clinical trial conducted at 9 academic European hospitals. Enrollment occurred from May 9, 2017, through October 7, 2020, with final follow-up on October 13, 2021. A total of 300 patients undergoing percutaneous coronary intervention (PCI) for AMI were randomized to receive biweekly subcutaneous alirocumab (150 mg; n=148) or placebo (n=152), initiated less than 24 hours after urgent PCI of the culprit lesion, for 52 weeks in addition to high-intensity statin therapy (rosuvastatin 20 mg).
Intravascular ultrasonography (IVUS), near-infrared spectroscopy (NIRS), and optical coherence tomography (OCT) were serially performed in the 2 non-infarct-related coronary arteries at baseline and after 52 weeks. The primary efficacy end point was the change in IVUS-derived percent atheroma volume (PAV) from baseline to week 52. Two powered secondary end points were changes in NIRS-derived maximum lipid core burden index within 4 mm (maxLCBI4mm; higher values indicating greater lipid content) and OCT-derived minimal fibrous cap thickness (minFCT; smaller values indicating thin-capped, vulnerable plaques) from baseline to week 52.
Why it matters
Who should read this
Opening member content…